| Filed On | Filing |
|---|---|
| 28 Oct 2026 |
8-K: Regulation FD Disclosure
MIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared With Semaglutide |
| 22 Oct 2026 |
8-K: Regulation FD Disclosure
MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study |
| 17 Sep 2026 |
8-K: Regulation FD Disclosure
MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review |
| 16 Sep 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On September 11, 2026, MIRA Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The record date for stockholders entitled to notice of the Annual Meeting was July 21, 2026 (the “Reco... |
| 01 Sep 2026 | 8-K: Regulation FD Disclosure |
| 06 Aug 2026 | 8-K: Regulation FD Disclosure |
| 31 Jul 2026 | 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule |
| 10 Jul 2026 | 8-K: Regulation FD Disclosure |
| 06 Jul 2026 | 8-K: Regulation FD Disclosure |
| 25 Jun 2026 | 8-K: Regulation FD Disclosure |
| 17 Jun 2026 | 8-K: Regulation FD Disclosure |
| 08 Jun 2026 | 8-K: Departure/Election of Directors or Officers; Compensation |
| 04 Jun 2026 | 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure |
| 27 May 2026 | 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure |
| 13 May 2026 | 8-K: Regulation FD Disclosure |
| 13 May 2026 | 8-K: Other Events |
| 23 Mar 2026 | 8-K: Other Events |
| 03 Mar 2026 | 8-K: Other Events |
| 02 Feb 2026 | 8-K: Other Events |
| 22 Dec 2025 | 8-K: Departure/Election of Directors or Officers; Compensation |
Loading...
